Simple Summary Pancreatic cancer presents a challenge due to its high mortality rates and
limited treatment options. In an effort to improve patient outcomes, neoadjuvant treatment …

Simple Summary Pancreatic ductal adenocarcinoma (PDAC) is currently one of the
deadliest cancers. Despite the progress that has been made in the research of patient care …

Abstract Alterations in KRAS, CDKN2A (p16), TP53, and SMAD4 genes have been major
drivers of pancreatic carcinogenesis. The clinical course of patients with pancreatic cancer …

Pancreatic cancer is one of the cancers with very poor prognosis; there is an urgent need to
identify novel biomarkers to improve its clinical outcomes. Circulating tumor DNA (ctDNA) …

Background Pancreatic ductal adenocarcinoma (PDAC) concomitant with intraductal
papillary mucinous neoplasm (IPMN) is defined as PDAC occurring apart from IPMN. This …

Simple Summary New therapeutic strategies are needed to improve the prognosis of
pancreatic ductal adenocarcinoma (PDAC) and developing biomarkers that can guide …

Simple Summary Pancreatic cancer is notorious for its poor prognosis. However, rare long-
term survivors of pancreatic cancer exist. The aim of this study was to characterize the …

Objectives Some intraductal papillary mucinous neoplasms (IPMNs) have malignant
potential and can become pancreatic cancer. The mechanism behind the malignant …

Background Although adjuvant gemcitabine (GEM) monotherapy improves the overall
survival (OS) of patients with resected pancreatic cancer, its efficacy requires further …

Single-nucleotide polymorphism (SNP) plays a key role in the carcinogenesis of the human
genome, and understanding the intrinsic relationship between individual genetic variations …